Search research articles
Contact Us
Filters
Showing results (261-270 of 328) with videos related to
Page
of 33
Sort By:
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
Cancer Discovery
|
December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Sonali M Smith, Kerri Wachter, Howard A Burris, et al.
Cancer Discovery
|
April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.
Nature Medicine
|
July 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
Matteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
Nature Communications
|
November 26, 2021
Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
Sanjay M Prakadan, Christopher A Alvarez-Breckenridge, Samuel C Markson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
Selina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Nature Communications
|
October 13, 2021
Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
Sanjay M Prakadan, Christopher A Alvarez-Breckenridge, Samuel C Markson, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Page
of 33
Search research articles
Search
Showing results (261-270 of 328) with videos related to
Sort By:
Page
of 33
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
Cancer Discovery
|
December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Sonali M Smith, Kerri Wachter, Howard A Burris, et al.
Cancer Discovery
|
April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.
Nature Medicine
|
July 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
Matteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
Nature Communications
|
November 26, 2021
Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
Sanjay M Prakadan, Christopher A Alvarez-Breckenridge, Samuel C Markson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
Selina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Nature Communications
|
October 13, 2021
Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
Sanjay M Prakadan, Christopher A Alvarez-Breckenridge, Samuel C Markson, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Page
of 33